The investigational drug SYS6043 for injection, developed by CSPC Innovation Pharmaceutical Co.,Ltd.'s (300765.SZ) controlling subsidiary CSPC Jushi Biotechnology Co., Ltd., has been included in the Breakthrough Therapy Designation list by the Center for Drug Evaluation of China's National Medical Products Administration.
Clinical study data for the drug in treating platinum-resistant ovarian cancer, primary peritoneal cancer, and fallopian tube cancer indicate that, compared to non-platinum monotherapy chemotherapy and the treatment regimen involving mirvetuximab soravtansine, SYS6043 demonstrates more durable anti-tumor activity. It has doubled patients' progression-free survival while maintaining a favorable overall safety profile.
The company has now formally initiated a Phase III confirmatory clinical trial for SYS6043 targeting the aforementioned indications, fully advancing its research, development, and market launch process. Concurrently, clinical trials for SYS6043 in first-line and second-line treatment of small cell lung cancer, breast cancer, and various other solid tumors are actively underway, with the multi-tumor R&D strategy progressing steadily.
The granting of Breakthrough Therapy Designation for SYS6043 is expected to significantly accelerate its overall clinical development timeline and the regulatory review and approval process across all targeted tumor types. This will facilitate the early market entry of this innovative drug, providing a new, high-quality treatment option for patients with advanced gynecological cancers.
Furthermore, this designation further enriches the company's oncology drug development pipeline. It continuously strengthens the company's differentiated R&D advantages and core market competitiveness in the field of Antibody-Drug Conjugates (ADCs), supporting the company's sustained commitment and development in the oncology innovative drug sector.
Comments